1. 1
Research and Publications
Lauren E. Guest
Peer-Reviewed Articles
1. Tapper, Elliot, Bacon, Bruce,Curry, Michael, Dieterich, Douglas, Flamm, Steven, Guest,
Lauren, Kowdley, Kris, Lee,Yoori, Tsai, Naoky, Younossi, Zobair, Afdhal, Nezam. 2016.
“Real-world effectiveness for 12 weeks of ledipasvir–sofosbuvir for genotype 1 hepatitis C: the
Trio Health study.” Journal of Viral Hepatitis 24(1): 22-27.
2. Guest, Lauren,Schap,David, Tran, Thi. 2015. “The ‘Loss of Chance’ Rule as a Special
Category of Damages in Medical Malpractice Cases:A State-by-State Analysis.” Journal of
Legal Economics 21(2): 53-107.
3. Schap, David, Baumann, Robert, Guest, Lauren. 2014. “Wage Net Discount Rates:1981-2012.”
Journal of Forensic Economics 25(2):153-174.
4. Guest, Lauren,Schap,David. 2014. “Rationales Concerning the Treatment of FederalIncome
Taxes in PersonalInjury and Wrongful Death Litigation in the State Courts.” Journal of Legal
Economics 21(1): 85-117.
5. Guest, Lauren,Schap,David. 2014. “Case Law Concerning the Treatment of Federal Income
Taxes in PersonalInjury and Wrongful Death Litigation in the State Courts.” Journal of Legal
Economics 20(1-2): 85-123.
6. Schap, David, Guest, Lauren,Kraynak,Andrew. 2013. “Total Offset and Medical Net Discount
Rates:1981-2012.” Journal of Forensic Economics 24(2): 191-204.
Conference Talks
1. Younossi, Zobair, Bacon, Bruce,Curry, Michael, Dieterich, Douglas, Flamm, Steven, Guest,
Lauren, Kowdley, Kris, Lee,Yoori, Tsai, Naoky, Afdhal, Nezam. 2016. “Access to Therapy in
Era of All DAA Regimens: Real World Experience from the TRIO Network.” Digestive Disease
Week. San Diego, California.
2. Kowdley, Kris, Bacon, Bruce,Curry, Michael, Dieterich, Douglas, Flamm, Steven, Guest,
Lauren, Lee,Yoori, Tsai, Naoky, Younossi, Zobair, Afdhal, Nezam. 2016.
“Ledipasvir/Sofosbuvir +/- Ribavirin in Patients Co-Infected with HCV and HIV:Real-World
Heterogeneous Population From the TRIO Network.” Digestive Disease Week. San Diego,
California.
3. Schap, David, Guest, Lauren. 2014. “The Loss of Chance Rule in Massachusetts.” Eastern
Region NAFE Meetings. Boston, Massachusetts.
4. Schap, David, Guest, Lauren. 2013. “Time Series Analysis of Wage Growth and Discount
Rates.” Eastern Region NAFE Meetings. Tampa, Florida.

2. 2
5. Schap, David, Guest, Lauren. 2013. “The Treatment of Income Taxes in PersonalInjury Cases:
A Summary of Various Rationales from the State Courts.” Allied Social Science Association
Annual Meeting. San Diego, California.
Conference Posters
1. Curry, Michael, Bacon, Bruce,Dieterich, Douglas, Flamm, Steven, Guest, Lauren,Kowdley,
Kris, Lee,Yoori, Tsai, Naoky, Younossi, Zobair. 2016. “Effectiveness of 12 or 24 Week LDV-
SOF and 12 Week LDV-SOF+RBV in Treatment-Experienced Patients with Cirrhotic, Genotype
1 Hepatitis C: Real-World Experience from the TRIO Network.” International Society for
Pharmacoeconomics and Outcomes Research AnnualMeeting. Washington, DC.
2. Curry, Michael, Bacon, Bruce,Dieterich, Douglas, Flamm, Steven, Guest, Lauren,Kowdley,
Kris, Lee,Yoori, Tsai, Naoky, Younossi, Zobair. 2016. “Effectiveness of 8 or 12 Week LDV-
SOF in Treatment-Naive Patients with Non-Cirrhotic, Genotype 1 Hepatitis C: Real-World
Experience from the TRIO Network.” International Society for Pharmacoeconomics and
Outcomes Research AnnualMeeting. Washington, DC.
3. Afdhal, Nezam, Bacon, Bruce,Curry, Michael, Dieterich, Douglas, Flamm, Steven, Guest,
Lauren, Kowdley, Kris, Lee,Yoori, Tsai, Naoky, Younossi, Zobair. 2016. “Failure with All-Oral
DAA Regimens: Real-World Experience from the TRIO Network.” Digestive Disease Week. San
Diego, California.
4. Afdhal, Nezam, Bacon, Bruce,Curry, Michael, Dieterich, Douglas, Flamm, Steven, Guest,
Lauren, Kowdley, Kris, Lee,Yoori, Tsai, Naoky, Younossi, Zobair. 2016. “No Effect of Proton
Pump Inhibitor (PPI) Use on SVR with Ledipasvir/Sofosbuvir (LDV/SOF): Real-World Data
from 2034 Genotype 1 Patients in the TRIO Network.” European Association for the Study of the
Liver International Liver Congress. Barcelona,Spain.1
5. Flamm, Steven, Bruce, Curry, Michael, Dieterich, Douglas, Flamm, Steven, Guest, Lauren,
Kowdley, Kris, Lee,Yoori, Tsai, Naoky, Younossi, Zobair, Afdhal, Nezam. 2016.
“Ledipasvir/Sofosbuvir+/-Ribavirin in HCV Post-Transplant Patients: Real-World Heterogeneous
Population from the TRIO Network.” European Association for the Study of the Liver
International Liver Congress. Barcelona, Spain.
6. Dieterich, Douglas, Bacon, Bruce,Curry, Michael, Dieterich, Douglas, Flamm, Steven, Guest,
Lauren, Kowdley, Kris, Lee,Yoori, Tsai, Naoky, Younossi, Zobair, Afdhal, Nezam. 2016.
“Ledipasvir/Sofosbuvir+/-Ribavirin in Patients Co-Infected with HCV and HIV: Real-World
Heterogeneous Population from the TRIO Network.” European Association for the Study of the
Liver International Liver Conference. Barcelona,Spain.
7. Flamm, Steven, Bruce, Curry, Michael, Dieterich, Douglas, Flamm, Steven, Guest, Lauren,
Kowdley, Kris, Lee,Yoori, Tsai, Naoky, Younossi, Zobair, Afdhal, Nezam. 2016.
“Ledipasvir/Sofosbuvir+/-Ribavirin in HCV Post-Transplant Patients: Real-World Heterogeneous
Population from the TRIO Network.” International Liver Transplantation Society Annual
International Congress. Seoul, Korea.
1 Accepted as a late-breaking abstract

3. 3
8. Afdhal, Nezam, Bacon, Bruce,Curry, Michael, Dieterich, Douglas, Flamm, Steven, Guest,
Lauren, Kowdley, Kris, Lee,Yoori, Tsai, Naoky, Younossi, Zobair. 2016. “Evaluation of
Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) for 12 Weeks in a Real-Life Population of
Genotype 1a and 1b HCV Patients; Data from the TRIO Network.” The Asian Pacific
Association for the Study of the Liver. Tokyo, Japan.
9. Tsai, Naoky, Bacon, Bruce,Curry, Michael, Dieterich, Douglas, Flamm, Steven, Guest, Lauren,
Kowdley, Kris, Lee,Yoori, Younossi, Zobair, Afdhal, Nezam. 2015. “Failure with All-Oral DAA
Regimens: Academic and Community Treatment of a Real-World Population from the TRIO
Network.” HepDART. Maui,Hawaii.
10. Dieterich, Douglas, Bacon, Bruce,Curry, Michael, Flamm, Steven, Guest, Lauren,Kowdley,
Kris, Lee,Yoori, Tsai, Naoky, Younossi, Zobair, Afdhal, Nezam. 2015. “Access to Therapy in
Era of All DAA Regimens: Real World Experience from the TRIO Network.” HepDART. Maui,
Hawaii.
11. Curry, Michael, Bacon, Bruce,Dieterich, Douglas, Flamm, Steven, Guest, Lauren,Kowdley,
Kris, Lee,Yoori, Tsai, Naoky, Younossi, Zobair. 2015. “Effectiveness of 8 or 12 week LDV-SOF
in Treatment-Naïve Patients with Non-Cirrhotic, Genotype 1 Hepatitis C: Real-World Experience
from the TRIO network.” American Association for the Study of Liver Diseases Annual Liver
Meeting. San Francisco, California.2
12. Curry, Michael, Bacon, Bruce,Dieterich, Douglas, Flamm, Steven, Guest, Lauren,Kowdley,
Kris, Lee,Yoori, Tsai, Naoky, Younossi, Zobair. 2015. “Effectiveness of 12 or 24 week LDV-
SOF and 12 week LDV-SOF + RBV in Treatment-Experienced Patients with Cirrhotic, Genotype
1 Hepatitis C: Real-World Experience from the TRIO network.” American Association for the
Study of Liver Diseases Annual Liver Meeting. San Francisco, California.
13. Afdhal, Nezam, Bacon, Bruce,Dieterich, Douglas, Flamm, Steven, Guest, Lauren,Kowdley,
Kris, Lee,Yoori, Tsai, Naoky, Younossi, Zobair. 2015. “Failure with All-Oral DAA Regimens:
Academic and Community Treatment of a Real-World Population from the TRIO Network.”
American Association for the Study of Liver Diseases Annual Liver Meeting. San Francisco,
California.3
Other Publications
1. Schap, David, Guest, Lauren,Kraynak,Andrew. 2014. “Total Offset and Medical Net Discount
Rates:1981-2012.” CUR Quarterly 34(3):23.
2 Recipient of the Presidential Poster Distinction Award
3 Accepted as a late-breaking abstract